Q-omics provides the consensus-scored ZNF658 profile across patient tissues and cancer cell-line models. ZNF658 expression is associated with patient survival in 24 of 34 cancer types, with the highest sampling consensus in KIRC. Among the 18 cancer types available for tumor–normal comparison, ZNF658 is differentially expressed in 11, with the highest sampling consensus in THCA. Additionally, ZNF658 RNA expression shows 20,893 significant gene co-expression associations, with the highest sampling consensus in UVM. Together, these results highlight KIRC, THCA, and UVM as cancer lineages where ZNF658 shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for ZNF658 — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes ZNF658 survival associations across molecular data types. ZNF658 RNA expression shows survival associations in the most cancer types (24), followed by mutation status (6) and mass-spec protein abundance (1). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible ZNF658 RNA expression–survival associations across cancer types. High ZNF658 expression shows unfavorable associations in ACC and KIRP, but favorable associations in KIRC, READ, HNSC and PAAD. The KIRC Kaplan–Meier curve shows clear separation, with the low-expression group declining faster, consistent with the favorable association (log-rank p < 0.001). Together, the overview and detailed table identify KIRC as the clearest survival context for ZNF658 RNA expression.
This table summarizes ZNF658 tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 11, while mass-spec protein shows differences in 1. The strongest signals are observed in THCA for RNA and PDAC for protein.
This table ranks reproducible tumor–normal expression differences for ZNF658. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. ZNF658 shows lower tumor expression in THCA, COAD, KICH, LUAD and BRCA and higher tumor expression in LIHC. The THCA box plot shows higher ZNF658 RNA expression in normal versus tumor tissue (log2 FC = −1.055, t-test p < 0.001).
This table shows molecular features associated with ZNF658 in patient tissues and cancer cell lines. In patient samples, ZNF658 shows the broadest associations at the RNA and protein expression levels, with UVM recurring as the lineage with the largest associated feature set. In cancer cell lines, ZNF658 RNA and mutation anchors are most strongly linked to RNA-expression features, especially in BLOOD_Lymphoma, while CRISPR and shRNA rows add functional-dependency signals in OVARY and LARGE_INTESTINE.
